Left ventricular infarct size assessed with 0.1 mmol/kg of gadobenate dimeglumine correlates with that assessed with 0.2 mmol/kg of gadopentetate dimeglumine

Journal of Computer Assisted Tomography

Volumn 33, Issue 3, 2009, Pages 328-333

  Tumkosit, Monravee ^a,b   Puntawangkoon, Chirapa ^a   Morgan, Tim M ^a   Clark, Hollins P ^a   Hamilton, Craig A ^a   Ntim, William O ^a   Clark, Paige B ^a   Hundley, W Gregory ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Contrast; Ischemic heart disease; Myocardial infarction

Indexed keywords

CARDIOLOGY; MAGNETIC RESONANCE;

BODY WEIGHT; CONTRAST; CONTRAST AGENT; GD-DTPA; INFARCT SIZE; ISCHEMIC HEART DISEASE; LEFT VENTRICULAR; MYOCARDIAL INFARCT SIZES; MYOCARDIAL INFARCTION; MYOCARDIAL INFARCTS;

ANTHROPOMETRY;

GADOBENATE DIMEGLUMINE; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; MAGNETOM AVANTO; UNCLASSIFIED DRUG; CONTRAST MEDIUM; DRUG DERIVATIVE; GADOBENIC ACID; MEGLUMINE; ORGANOMETALLIC COMPOUND;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE; HEART VOLUME; HUMAN; ISCHEMIC HEART DISEASE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STATISTICS;

CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HEART VENTRICLES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MEGLUMINE; MIDDLE AGED; MYOCARDIAL INFARCTION; ORGANOMETALLIC COMPOUNDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STATISTICS AS TOPIC; VENTRICULAR DYSFUNCTION, LEFT;

EID: 67649119602     PISSN: 03638715     EISSN: None     Source Type: Journal    
DOI: 10.1097/RCT.0b013e318187fed0     Document Type: Article

References (25)

1. Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000;343:1445-1453.
2. Edelman RR. Contrast-enhanced MR imaging of the heart: overview of the literature. Radiology. 2004;232:653-668.
3. Petersen SE, Mohrs OK, Horstick G, et al. Influence of contrast agent dose and image acquisition timing on the quantitative determination of nonviable myocardial tissue using delayed contrast-enhanced magnetic resonance imaging. J Cardiovasc Magn Reson. 2004;6:541-548.
4. Kim RJ, Fieno DS, Parrish TB, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999;100:1992-2202.
5. Perazella MA, Rodby RA. Gadolinium use in patients with kidney disease: a cause for concern. Semin Dial. 2007;20:179-185.
6. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology. 2007;243:148-157.
7. Collidge TA, Thomson PC, Mark PB, et al. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology. 2007;245:168-175.
8. Cavagna FM, Maggioni F, Castelli PM, et al. Gadolinium chelates with weak binding to serum proteins. Invest Radiol. 1997;32:780-796.
9. Prokop M, Schneider G, Vanzulli A, et al. Contrast-enhanced MR angiography of the renal arteries: blinded multicenter crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. Radiology. 2005;234:399-408.
10. Alpert JS, Thygesen K, Antman E, et al. Myocardial infarction redefined - a consensus document of The Joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000;36:959-969.
11. Schlosser T, Hunold P, Herborn CU, et al. Myocardial infarct: depiction with contrast-enhanced MR imaging - comparison of gadopentetate and gadobenate. Radiology. 2005;236:1041-1046.
12. Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. Circulation. 2002;105:539-542.
13. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-310.
14. Fleiss JL. The Design and Analysis of Clinical Experiments. 1st ed. New York, NY: John Wiley & Sons, 1986; 432.
15. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-174.
16. Holman ER, van Rossum AC, Doesburg T, et al. Assessment of acute myocardial infarction in man with magnetic resonance imaging and the use of a new paramagnetic contrast agent gadolinium-BOPTA. Magn Reson Imaging. 1996;14:21-29.
17. Kuwatsuru R, Kadoya M, Ohtomo K, et al. Comparison of gadobenate dimeglumine with gadopentetate dimeglumine for magnetic resonance imaging of liver tumor. Invest Radiol. 2001;36:632-641.
18. Colosimo C, Demaerel P, Tortori-Donati P, et al. Comparison of gadobenate dimeglumine (Gd-BOPTA) with gadopentetate dimeglumine (Gd-DTPA) for enhanced MR imaging of brain and spine tumors in children. Pediatr Radiol. 2005;35:501-510.
19. Sardanelli F, Quarenghi M. Delayed enhancement of subendocardial infracted myocardium with gadobenate dimeglumine: a paradoxical effect - is a double dose too much? Radiology. 2006;240:915.
20. Balci NC, Inan N, Anik Y, et al. Low-dose gadobenate dimeglumine for delayed contrast-enhanced cardiac magnetic resonance imaging. Acad Radiol. 2006;13:833-839.
21. Beanlands RS, Ruddy TD, deKemp RA, et al. Positron emission tomography and recovery following revascularization (PARR-1): the importance of scar and the development of a prediction rule for the degree of recovery of left ventricular function. J Am Coll Cardiol. 2000;40:1735-1743.
22. Kim RJ. Diagnostic testing. J Am Coll Cardiol. 2006;47:D23-D27.
23. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21:1104-1108.
24. Broome DR, Girguis MS, Baron PW, et al. Gadiodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol. 2007;188:586-592.
25. Wagner A, Mahrholdt H, Thomson L, et al. Effects of time, dose, and inversion time for acute myocardial infarct size measurements based on magnetic resonance imaging-delayed contrast enhancement. J Am Coll Cardiol. 2006;47:2027-2033.